E. Panic (Sombor, Yugoslavia), J. Sorli (Golnik, Slovenia)
Two-year experience of DOTS implementation – weaknesses and achievements
S. Talevski, A. Vidoevska, B. Ilievska-Poposka, L. Simonovska, M. Trajcevska, N. Milanovski, S. Atanasova, A. Sandevski, G. Bikova (Skopje, Macedonia)
|  |
Cost-effectiveness of the DOTS strategy of tuberculosis control in Iasi County, Romania
Z. Tarevici, R. Centis, J. P. Zellweger, T. Mihaescu, G. B. Migliori (Iasi, Romania; Tradate, Italy; Lausanne, Switzerland)
| |
Relapse rate in tuberculosis patients folowed-up in two dispensaries in Istanbul
Z. Kilicaslan, F. Ozturk, N. Sarimurat, D. Polat, C. Kucuk, E. Pekdemir (Istanbul, Turkey)
| |
Tuberculosis treatment defaulters in a Greek hospital
D. A. Makris, A. Damianaki, A. Gkinosati, S. Moschakou, M. Moschonas, E. Ntaoukakis (Chania, Greece)
| |
Reasons of ineffective DOTS in prison: amplification and mixed infection
S. Mishustin, A. Adamyan, E. Andreev, A. Barnashov, L. Blinova, N. Kurepina, B. Kreiswirth (Tomsk, Russia; New York, United States Of America)
| |
Tuberculosis treatment at a prison in Lima, Peru: risk factors to failure
E. Santiago, J. Best, J. Leey, R. Accinelli (Lima, Peru)
| |
Enhanced clinical improvement in pulmonary tuberculosis patients with antioxidant supplementation: a preliminary report
M. S. Shelgaonkar, R. P. Munje, S. D. Shelgaonkar, S. N. Umathe (Nagpur, India)
| |
Efficacy of standard chemotherapy regimen in patients with newly detected sputum-positive destructive pulmonary tuberculosis
N. A. Litvinenko, E. V. Ivankova, O. E. Begoulev (Kiev, Ukraine)
| |
Long term plasma rifampicin (R) concentrations in AIDS patients with tuberculosis (TB) under HAART therapy
M. A. Vieira, M. Ferreira-Filho, D. Pinto, V. Rolla, E. Werneck-Barroso (Rio Jeneiro, Brazil)
| |
Adverse effects in patients receiving therapy for multi-drug resistant tuberculosis in Latvia
G. Dravniece, V. Leimane, V. Skripconoka (Riga Region, Latvia)
| |
The peculiarities of course and treatment of pulmonary tuberculosis with initial drug resistance
D. Krasnov, V. Krasnov, S. Naryshkina, A. Andrenko, V. Potashova (Novosibirsk, Russia)
| |
Efficacy of a standard chemotherapy regimen in the management of sputum-positive pulmonary TB relapses
V. Y. Mishin, S. N. Zhestovskikh (Moscow, Russia)
| |
Drug resistance of Mycobacterium tuberculosis to fluoroquinolones (Q)
M. S. Cherenko, A. A. Ghurilo, A. I. Barbova, M. Klimenko (Kiev, Ukraine)
| |
The expansion of the dots strategy in Lithuania
E. Davidaviciene, D. Gaidamoniene, A. Sosnovskaja, I. Demsiene, R. Steigviliene, A. Petraskaite, E. ALeksaite (Vilnius, Lithuania)
| |
Urine excretion study of rifampicin in patients with tuberculosis co-infected with HIV
A. N. Mandke (Amargadh, Bhavnagar, India)
| |
Treatment outcomes of tuberculosis (TB) patients with rifampin (RMP) or RMP and isoniazid (INH) resistance receiving standard regimen
H. Tereci, O. Tumer, H. Solak, N. Adiguzel, S. Oztas, M. Kurutepe (Istanbul, Turkey)
| |
Causes of therapeutical failure in tuberculosis
C. M. Pop, R. M. Gherasim, C. D. Zamora, M. A. Man, M. A. T. Goron (Cluj-Napoca, Romania)
| |
Primary drug resistance rates in pulmonary tuberculosis
O. Deniz, F. Ciftci, E. Bozkanat, E. Demirer, M. Ozkan, I. Yuksekol, N. Ardic, K. Ekiz, N. Demirci (Istanbul, Ankara, Turkey)
| |
A community tuberculosis (TB) management model: an academic centre/public health department partnership
T. R. Aksamit, M. A. Schryver, J. W. Wilson, M. C. Scalcini, W. M. Brutinel, T. G. Boyce, L. Edmonson, M. Wellik, M. D. Brennan (Rochester, United States Of America)
| |
Our experience and treatment results of multidrug-resistant tuberculosis (MDR-TB) patients between 1996-2002
O. Tumer, H. Solak, N. Adiguzel, F. Ayata, I. Baluken, M. Kurutepe (Istanbul, Turkey)
| |